Meeting
2022 ASCO Annual Meeting
In-vivo reprogramming macrophages and dendritic cells with Allocetra-OTS: Successful mono- and combination-antitumor therapy.
Authors
Dror Mevorach
Hadassah Medical Center, Jerusalem, Israel
Dror Mevorach , Yehudit Shabat , Eshchar Regev , Eran Yalon , Netanel Karbian , Barak Reicher
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Cellular Immmunotherapy
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2532)
DOI
10.1200/JCO.2022.40.16_suppl.2532
Abstract #
2532
Poster Bd #
188
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Phase 1 trial of gavocabtagene autoleucel (gavo-cel, TC-210) in patients (pts) with treatment refractory mesothelioma and other mesothelin-expressing solid tumors.
First Author: Raffit Hassan
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Effect of dendritic cells (DC) transduced with chimeric antigen receptor (CAR) on CAR T-cell cytotoxicity.
First Author: Hyung Chan Suh
Poster
2022 ASCO Annual Meeting
First-in-human phase 1/2 study of autologous T cells engineered using the Sleeping Beauty System transposon/transposase to express T-cell receptors (TCRs) reactive against cancer-specific mutations in patients with advanced solid tumors.
First Author: Marcelo Vailati Negrao
Poster
2022 ASCO Gastrointestinal Cancers Symposium
High-risk gene expression in colorectal liver metastasis: Potential for novel therapies.
First Author: Caroline Medin